Skip to main content

Compare Stocks

Date Range: 

 AraviveMerrimack PharmaceuticalsHelix BioPharmaKazia TherapeuticsAileron Therapeutics
SymbolNASDAQ:ARAVNASDAQ:MACKOTCMKTS:HBPCFNASDAQ:KZIANASDAQ:ALRN
Price Information
Current Price$4.65$6.04$0.76$10.01$1.17
52 Week RangeBuyN/AN/ABuyBuy
MarketRank™
Overall Score1.61.10.51.21.3
Analysis Score3.40.00.03.53.5
Community Score2.52.92.31.92.6
Dividend Score0.00.00.00.00.0
Ownership Score0.82.50.00.00.0
Earnings & Valuation Score1.30.00.00.60.6
Analyst Ratings
Consensus RecommendationBuyN/AN/ABuyBuy
Consensus Price Target$25.20N/AN/A$17.00$3.50
% Upside from Price Target441.94% upsideN/AN/A69.83% upside199.15% upside
Trade Information
Market Cap$94.80 million$81.00 million$107.80 million$94.70 million$105.65 million
Beta3.22.550.042.763.13
Average Volume213,05280,8561,665145,5883,252,119
Sales & Book Value
Annual Revenue$4.75 millionN/AN/A$710,000.00N/A
Price / Sales19.96N/AN/A133.37N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$4.71 per share$1.30 per share$0.02 per share$1.00 per share$0.58 per share
Price / Book0.99N/AN/A10.01N/A
Profitability
Net Income$-18,220,000.00$-17,330,000.00$-6,680,000.00$-8,370,000.00$-29,370,000.00
EPS($1.57)N/AN/A($1.30)($1.20)
Trailing P/E RatioN/A0.000.00N/AN/A
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)-47.21%-14.94%-325.42%N/A-170.37%
Return on Assets (ROA)-39.11%-12.96%-193.46%N/A-98.29%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.03%
Current Ratio11.37%8.42%2.22%2.10%3.04%
Quick Ratio11.37%8.42%2.22%2.10%3.04%
Ownership Information
Institutional Ownership Percentage40.54%52.25%N/A10.49%6.67%
Insider Ownership Percentage30.50%21.60%7.60%1.00%6.20%
Miscellaneous
Employees172710N/A8
Shares Outstanding20.39 million13.41 million141.13 million9.46 million90.30 million
Next Earnings Date8/2/2021 (Estimated)5/13/2021 (Estimated)7/29/2021 (Estimated)N/A8/4/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Aileron Therapeutics (NASDAQ:ALRN) Announces  Earnings ResultsAileron Therapeutics (NASDAQ:ALRN) Announces Earnings Results
americanbankingnews.com - May 12 at 12:24 PM
Aileron Therapeutics (NASDAQ:ALRN) Research Coverage Started at HC WainwrightAileron Therapeutics (NASDAQ:ALRN) Research Coverage Started at HC Wainwright
americanbankingnews.com - May 12 at 8:39 AM
Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdateAileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 11 at 6:17 PM
 Brokerages Anticipate Aileron Therapeutics, Inc. (NASDAQ:ALRN) Will Post Earnings of -$0.06 Per Share Brokerages Anticipate Aileron Therapeutics, Inc. (NASDAQ:ALRN) Will Post Earnings of -$0.06 Per Share
americanbankingnews.com - May 9 at 1:05 AM
When is Aileron Therapeutics Inc. (ALRN) going to be good investment?When is Aileron Therapeutics Inc. (ALRN) going to be good investment?
marketingsentinel.com - May 5 at 1:45 PM
Aileron Therapeutics, Inc. (NASDAQ:ALRN)’s Upside Potential Is HighAileron Therapeutics, Inc. (NASDAQ:ALRN)’s Upside Potential Is High
stocksregister.com - May 1 at 1:57 PM
Aileron Therapeutics Inc (ALRN)Aileron Therapeutics Inc (ALRN)
investing.com - April 25 at 8:10 AM
Aileron Therapeutics, Inc. (NASDAQ:ALRN) up 73.97% from 52-Week Low; YTD rises 16.35% – Here’s What to Do NowAileron Therapeutics, Inc. (NASDAQ:ALRN) up 73.97% from 52-Week Low; YTD rises 16.35% – Here’s What to Do Now
marketingsentinel.com - April 24 at 2:34 PM
 Analysts Anticipate Aileron Therapeutics, Inc. (NASDAQ:ALRN) Will Post Earnings of -$0.06 Per Share Analysts Anticipate Aileron Therapeutics, Inc. (NASDAQ:ALRN) Will Post Earnings of -$0.06 Per Share
americanbankingnews.com - April 21 at 4:24 PM
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest UpdateAileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Update
americanbankingnews.com - April 19 at 4:48 AM
Let’s Jump into the Aileron Therapeutics, Inc. (NASDAQ:ALRN) Stock ForecastLet’s Jump into the Aileron Therapeutics, Inc. (NASDAQ:ALRN) Stock Forecast
marketingsentinel.com - March 29 at 1:45 PM
William Blair lifts Aileron Therapeutics Inc. [ALRN] price estimate. Who else is bullish?William Blair lifts Aileron Therapeutics Inc. [ALRN] price estimate. Who else is bullish?
dbtnews.com - March 26 at 6:34 PM
Aileron Therapeutics, Inc. (NASDAQ:ALRN) – An Analysis Is What You NeedAileron Therapeutics, Inc. (NASDAQ:ALRN) – An Analysis Is What You Need
stocksregister.com - March 26 at 8:33 AM
Aileron Therapeutics, Inc. (NASDAQ:ALRN) share price rebounds 80.89% from the lows – but can it keep going?Aileron Therapeutics, Inc. (NASDAQ:ALRN) share price rebounds 80.89% from the lows – but can it keep going?
marketingsentinel.com - March 25 at 12:29 PM
Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides ...Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides ...
apnews.com - March 24 at 7:25 PM
Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business HighlightsAileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
finance.yahoo.com - March 24 at 7:25 PM
Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences ConferenceAileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 4 at 12:52 PM
Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences ConferenceAileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 4 at 12:52 PM
Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ...Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ...
apnews.com - March 2 at 7:42 AM
Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
finance.yahoo.com - March 2 at 7:42 AM
Aileron Therapeutics, Inc. (ALRN) has great growth outlook for 2021Aileron Therapeutics, Inc. (ALRN) has great growth outlook for 2021
marketingsentinel.com - February 11 at 12:26 AM
Aileron Therapeutics Inc. [ALRN] Stock trading around $1.99 per share: What’s Next?Aileron Therapeutics Inc. [ALRN] Stock trading around $1.99 per share: What’s Next?
dbtnews.com - February 5 at 6:11 PM
Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment PartnersAileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners
finance.yahoo.com - January 11 at 9:33 AM
Aileron Announces $35.9 Mln Registered Direct Offering; Stock DownAileron Announces $35.9 Mln Registered Direct Offering; Stock Down
nasdaq.com - January 6 at 3:17 PM
Aileron Therapeutics Announces $35.9 Million Registered Direct OfferingAileron Therapeutics Announces $35.9 Million Registered Direct Offering
finance.yahoo.com - January 6 at 10:14 AM
DateCompanyBrokerageAction
4/27/2021AraviveHC WainwrightReiterated Rating
3/15/2021AraviveBTIG ResearchInitiated Coverage
11/9/2020AravivePiper SandlerLower Price Target
9/18/2020AraviveWilliam BlairInitiated Coverage
8/14/2020AraviveWedbushReiterated Rating
8/13/2020AraviveCantor FitzgeraldReiterated Rating
12/20/2019AravivePiper Jaffray CompaniesReiterated Rating
12/2/2019AraviveRobert W. BairdUpgrade
11/7/2018Merrimack PharmaceuticalsCowenReiterated Rating
6/25/2018Merrimack PharmaceuticalsJPMorgan Chase & Co.Downgrade
11/16/2020Aileron TherapeuticsCanaccord GenuityReiterated Rating
(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.